A double-blind, placebo-controlled study of atomoxetine in young children with ADHD

Christopher J Kratochvil, Brigette S. Vaughan, Julie A. Stoner, Joan M. Daughton, Brian D. Lubberstedt, Desiree W. Murray, Allan K. Chrisman, Melissa A. Faircloth, Nilda B. Itchon-Ramos, Scott H. Kollins, Lawrence A. Maayan, Laurence L. Greenhill, Lisa A. Kotler, Jane Fried, John S. March

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

OBJECTIVE: To evaluate the efficacy and tolerability of atomoxetine for the treatment of attention-deficit/hyperactivity disorder (ADHD) in 5-and 6-year-old children. METHODS: This was an 8-week, double-blind, placebo-controlled randomized clinical trial of atomoxetine in 101 children with ADHD. Atomoxetine or placebo was flexibly titrated to a maximum dose of 1.8 mg/kg per day. The pharmacotherapist reviewed psychoeducational material on ADHD and behavioral-management strategies with parents during each study visit. RESULTS: Significant mean decreases in parent (P = .009) and teacher (P = .02) ADHD-IV Rating Scale scores were demonstrated with atomoxetine compared with placebo. A total of 40% of children treated with atomoxetine met response criteria (Clinical Global Impression-Improvement Scale indicating much or very much improved) compared with 22% of children on placebo, which was not significant (P=.1). Decreased appetite, gastrointestinal upset, and sedation were significantly more common with atomoxetine than placebo. Although some children demonstrated a robust response to atomoxetine, for others the response was more attenuated. Sixty-two percent of subjects who received atomoxetine were moderately, markedly, or severely ill according to the Clinical Global Impression-Severity Scale at study completion. CONCLUSIONS: To our knowledge, this is the first randomized controlled trial of atomoxetine in children as young as 5 years. Atomoxetine generally was well tolerated and reduced core ADHD symptoms in the children on the basis of parent and teacher reports. Reductions in the ADHD-IV Rating Scale scores, however, did not necessarily translate to overall clinical and functional improvement, as demonstrated on the Clinical Global Impression-Severity Scale and the Clinical Global Impression-Improvement Scale. Despite benefits, the children in the atomoxetine group remained, on average, significantly impaired at the end of the study.

Original languageEnglish (US)
JournalPediatrics
Volume127
Issue number4
DOIs
StatePublished - Apr 1 2011

Fingerprint

Attention Deficit Disorder with Hyperactivity
Placebos
Atomoxetine Hydrochloride
Randomized Controlled Trials
Appetite
Parents

Keywords

  • ADHD
  • Atomoxetine
  • Child
  • Pharmacotherapy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Kratochvil, C. J., Vaughan, B. S., Stoner, J. A., Daughton, J. M., Lubberstedt, B. D., Murray, D. W., ... March, J. S. (2011). A double-blind, placebo-controlled study of atomoxetine in young children with ADHD. Pediatrics, 127(4). https://doi.org/10.1542/peds.2010-0825

A double-blind, placebo-controlled study of atomoxetine in young children with ADHD. / Kratochvil, Christopher J; Vaughan, Brigette S.; Stoner, Julie A.; Daughton, Joan M.; Lubberstedt, Brian D.; Murray, Desiree W.; Chrisman, Allan K.; Faircloth, Melissa A.; Itchon-Ramos, Nilda B.; Kollins, Scott H.; Maayan, Lawrence A.; Greenhill, Laurence L.; Kotler, Lisa A.; Fried, Jane; March, John S.

In: Pediatrics, Vol. 127, No. 4, 01.04.2011.

Research output: Contribution to journalArticle

Kratochvil, CJ, Vaughan, BS, Stoner, JA, Daughton, JM, Lubberstedt, BD, Murray, DW, Chrisman, AK, Faircloth, MA, Itchon-Ramos, NB, Kollins, SH, Maayan, LA, Greenhill, LL, Kotler, LA, Fried, J & March, JS 2011, 'A double-blind, placebo-controlled study of atomoxetine in young children with ADHD', Pediatrics, vol. 127, no. 4. https://doi.org/10.1542/peds.2010-0825
Kratochvil, Christopher J ; Vaughan, Brigette S. ; Stoner, Julie A. ; Daughton, Joan M. ; Lubberstedt, Brian D. ; Murray, Desiree W. ; Chrisman, Allan K. ; Faircloth, Melissa A. ; Itchon-Ramos, Nilda B. ; Kollins, Scott H. ; Maayan, Lawrence A. ; Greenhill, Laurence L. ; Kotler, Lisa A. ; Fried, Jane ; March, John S. / A double-blind, placebo-controlled study of atomoxetine in young children with ADHD. In: Pediatrics. 2011 ; Vol. 127, No. 4.
@article{104135fda8ee4413ad843165132c4bbe,
title = "A double-blind, placebo-controlled study of atomoxetine in young children with ADHD",
abstract = "OBJECTIVE: To evaluate the efficacy and tolerability of atomoxetine for the treatment of attention-deficit/hyperactivity disorder (ADHD) in 5-and 6-year-old children. METHODS: This was an 8-week, double-blind, placebo-controlled randomized clinical trial of atomoxetine in 101 children with ADHD. Atomoxetine or placebo was flexibly titrated to a maximum dose of 1.8 mg/kg per day. The pharmacotherapist reviewed psychoeducational material on ADHD and behavioral-management strategies with parents during each study visit. RESULTS: Significant mean decreases in parent (P = .009) and teacher (P = .02) ADHD-IV Rating Scale scores were demonstrated with atomoxetine compared with placebo. A total of 40{\%} of children treated with atomoxetine met response criteria (Clinical Global Impression-Improvement Scale indicating much or very much improved) compared with 22{\%} of children on placebo, which was not significant (P=.1). Decreased appetite, gastrointestinal upset, and sedation were significantly more common with atomoxetine than placebo. Although some children demonstrated a robust response to atomoxetine, for others the response was more attenuated. Sixty-two percent of subjects who received atomoxetine were moderately, markedly, or severely ill according to the Clinical Global Impression-Severity Scale at study completion. CONCLUSIONS: To our knowledge, this is the first randomized controlled trial of atomoxetine in children as young as 5 years. Atomoxetine generally was well tolerated and reduced core ADHD symptoms in the children on the basis of parent and teacher reports. Reductions in the ADHD-IV Rating Scale scores, however, did not necessarily translate to overall clinical and functional improvement, as demonstrated on the Clinical Global Impression-Severity Scale and the Clinical Global Impression-Improvement Scale. Despite benefits, the children in the atomoxetine group remained, on average, significantly impaired at the end of the study.",
keywords = "ADHD, Atomoxetine, Child, Pharmacotherapy",
author = "Kratochvil, {Christopher J} and Vaughan, {Brigette S.} and Stoner, {Julie A.} and Daughton, {Joan M.} and Lubberstedt, {Brian D.} and Murray, {Desiree W.} and Chrisman, {Allan K.} and Faircloth, {Melissa A.} and Itchon-Ramos, {Nilda B.} and Kollins, {Scott H.} and Maayan, {Lawrence A.} and Greenhill, {Laurence L.} and Kotler, {Lisa A.} and Jane Fried and March, {John S.}",
year = "2011",
month = "4",
day = "1",
doi = "10.1542/peds.2010-0825",
language = "English (US)",
volume = "127",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "4",

}

TY - JOUR

T1 - A double-blind, placebo-controlled study of atomoxetine in young children with ADHD

AU - Kratochvil, Christopher J

AU - Vaughan, Brigette S.

AU - Stoner, Julie A.

AU - Daughton, Joan M.

AU - Lubberstedt, Brian D.

AU - Murray, Desiree W.

AU - Chrisman, Allan K.

AU - Faircloth, Melissa A.

AU - Itchon-Ramos, Nilda B.

AU - Kollins, Scott H.

AU - Maayan, Lawrence A.

AU - Greenhill, Laurence L.

AU - Kotler, Lisa A.

AU - Fried, Jane

AU - March, John S.

PY - 2011/4/1

Y1 - 2011/4/1

N2 - OBJECTIVE: To evaluate the efficacy and tolerability of atomoxetine for the treatment of attention-deficit/hyperactivity disorder (ADHD) in 5-and 6-year-old children. METHODS: This was an 8-week, double-blind, placebo-controlled randomized clinical trial of atomoxetine in 101 children with ADHD. Atomoxetine or placebo was flexibly titrated to a maximum dose of 1.8 mg/kg per day. The pharmacotherapist reviewed psychoeducational material on ADHD and behavioral-management strategies with parents during each study visit. RESULTS: Significant mean decreases in parent (P = .009) and teacher (P = .02) ADHD-IV Rating Scale scores were demonstrated with atomoxetine compared with placebo. A total of 40% of children treated with atomoxetine met response criteria (Clinical Global Impression-Improvement Scale indicating much or very much improved) compared with 22% of children on placebo, which was not significant (P=.1). Decreased appetite, gastrointestinal upset, and sedation were significantly more common with atomoxetine than placebo. Although some children demonstrated a robust response to atomoxetine, for others the response was more attenuated. Sixty-two percent of subjects who received atomoxetine were moderately, markedly, or severely ill according to the Clinical Global Impression-Severity Scale at study completion. CONCLUSIONS: To our knowledge, this is the first randomized controlled trial of atomoxetine in children as young as 5 years. Atomoxetine generally was well tolerated and reduced core ADHD symptoms in the children on the basis of parent and teacher reports. Reductions in the ADHD-IV Rating Scale scores, however, did not necessarily translate to overall clinical and functional improvement, as demonstrated on the Clinical Global Impression-Severity Scale and the Clinical Global Impression-Improvement Scale. Despite benefits, the children in the atomoxetine group remained, on average, significantly impaired at the end of the study.

AB - OBJECTIVE: To evaluate the efficacy and tolerability of atomoxetine for the treatment of attention-deficit/hyperactivity disorder (ADHD) in 5-and 6-year-old children. METHODS: This was an 8-week, double-blind, placebo-controlled randomized clinical trial of atomoxetine in 101 children with ADHD. Atomoxetine or placebo was flexibly titrated to a maximum dose of 1.8 mg/kg per day. The pharmacotherapist reviewed psychoeducational material on ADHD and behavioral-management strategies with parents during each study visit. RESULTS: Significant mean decreases in parent (P = .009) and teacher (P = .02) ADHD-IV Rating Scale scores were demonstrated with atomoxetine compared with placebo. A total of 40% of children treated with atomoxetine met response criteria (Clinical Global Impression-Improvement Scale indicating much or very much improved) compared with 22% of children on placebo, which was not significant (P=.1). Decreased appetite, gastrointestinal upset, and sedation were significantly more common with atomoxetine than placebo. Although some children demonstrated a robust response to atomoxetine, for others the response was more attenuated. Sixty-two percent of subjects who received atomoxetine were moderately, markedly, or severely ill according to the Clinical Global Impression-Severity Scale at study completion. CONCLUSIONS: To our knowledge, this is the first randomized controlled trial of atomoxetine in children as young as 5 years. Atomoxetine generally was well tolerated and reduced core ADHD symptoms in the children on the basis of parent and teacher reports. Reductions in the ADHD-IV Rating Scale scores, however, did not necessarily translate to overall clinical and functional improvement, as demonstrated on the Clinical Global Impression-Severity Scale and the Clinical Global Impression-Improvement Scale. Despite benefits, the children in the atomoxetine group remained, on average, significantly impaired at the end of the study.

KW - ADHD

KW - Atomoxetine

KW - Child

KW - Pharmacotherapy

UR - http://www.scopus.com/inward/record.url?scp=79953328093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953328093&partnerID=8YFLogxK

U2 - 10.1542/peds.2010-0825

DO - 10.1542/peds.2010-0825

M3 - Article

VL - 127

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 4

ER -